WT1 and acute myeloid leukemia: Chapuis et al. treated 12 AML patients relapsed after allogeneic HCT with anti-WT1 CAR-T cells; all of the patients responded, with a relapse-free survival of 100% at a median of 44 months, compared to 54% in patients not receiving CAR-T cell therapy.